Anti-PD1 antibody [EPR4877(2)] (Ab137132)
CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1
详细信息
背景信息
Anti-PD1 antibody [EPR4877(2)] (ab137132) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P. Anti-PD1 antibody [EPR4877(2)] (ab137132) was first used in a scientific publication in 2014 and has been cited over 101 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-PD1 antibody [EPR4877(2)] (ab137132) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-PD1 antibody [EPR4877(2)] (ab137132) has 5 independent reviews from customers. Anti-PD1 antibody [EPR4877(2)] (ab137132) specifically detects PD1 (UniProt ID: Q15116; Molecular weight: 29kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR4877(2) - ab186928. Antibody clone EPR4877(2) is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, Alexa Fluor ® 555, Alexa Fluor ® 594, Alexa Fluor ® 488, Alexa Fluor ® 568, Alexa Fluor ® 750 ( ab201825, ab275126, ab275349, ab311022, ab313074, ab321110 ). PD-1 is an immune checkpoint receptor that, when engaged by its ligands PD-L1 or PD-L2, inhibits T-cell activity, allowing tumors to evade immune detection. Blocking the PD-1 pathway with immune checkpoint inhibitors reactivates T-cells, enhancing the immune system's ability to target and destroy cancer cells. Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (118)
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
癌症引起的神经损伤会促进对PD-1抑制剂的耐药性
Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma
转移性黑色素瘤获得性免疫治疗耐药的基因组介质
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
独特的CD8+ T细胞动态变化与新辅助癌症免疫疗法的疗效相关
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma.
TP53 相关组织重塑的细胞和空间图谱定义了肺腺癌中的多细胞肿瘤生态系统。
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).
在无法切除的局部晚期食管鳞状细胞癌患者中,接受根治性放化疗后使用阿特珠单抗治疗——一项多中心 2 期试验 (EPOC1802)
Cell populations in human breast cancers are molecularly and biologically distinct with age.
人类乳腺癌细胞群在分子和生物学上随年龄而变化。
Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma
NF2相关神经鞘瘤病前庭神经鞘瘤中免疫细胞环境的空间分布图谱
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial
帕博利珠单抗联合化疗一线治疗晚期卵巢癌:一项 II 期试验的临床和转化结果
Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy
治疗应激触发肿瘤STAT1乙酰化,从而削弱免疫疗法
PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.
基于肿瘤细胞和免疫细胞中表达的 PD-L1 表型分类作为优化 NSCLC 中抗 PD-1/CTLA-4 免疫疗法的潜在生物标志物。
- 1
- 2
- 3
- 4
- 5
- 6
- 12